TY  - JOUR
A1  - Burger, Michael Christian
A1  - Breuer, Stella
A1  - Cieplik, Hans
A1  - Harter, Patrick Nikolaus
A1  - Franz, Kea
A1  - Bähr, Roy Oliver
A1  - Steinbach, Joachim Peter
T1  - Bevacizumab for patients with recurrent multifocal glioblastomas
T2  - International journal of molecular sciences
N2  - In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still more controversial. Therefore, we prepared a retrospective case series with 16 patients suffering from a multifocal glioblastoma treated with BEV. We compared these patients to a matched control cohort of 16 patients suffering from glioblastoma with a single lesion treated with BEV. The objective of this study was to evaluate whether the course of disease differs in glioblastoma patients with a multifocal disease pattern compared to those with a single lesion only. Patients were treated with BEV monotherapy or BEV in combination with irinotecan or lomustine (CCNU). Response rates and PFS were similar in both groups. There was a trend for an unfavorable OS in the patient group with multifocal glioblastoma, which was expected due to the generally worse prognosis of multifocal glioblastoma. We investigated whether BEV therapy affects the invasive growth pattern as measured by the appearance of new lesions on magnetic resonance imaging (MRI). Under BEV therapy, there was a trend for a lower frequency of new lesions both in multifocal and solitary glioblastoma. Based on these results, BEV therapy at relapse appears to be justified to no lesser extent in multifocal glioblastoma than in solitary glioblastoma.
KW  - glioblastoma
KW  - multifocal
KW  - bevacizumab
KW  - anti-angiogenic therapy
KW  - invasive growth
KW  - infiltration
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45162
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-451626
SN  - 2352-3409
N1  - © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
VL  - 18
IS  - 11, Art. 2469
SP  - 1
EP  - 11
PB  - Molecular Diversity Preservation International
CY  - Basel
ER  -